MiMedx Group (MDXG) Gets a Buy from Lake Street

In a report released today, Brooks O’Neil from Lake Street reiterated a Buy rating on MiMedx Group, with a price target of $10.00.

Claim 50% Off TipRanks Premium

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

According to TipRanks, O’Neil is an analyst with an average return of -1.4% and a 40.06% success rate.

In addition to Lake Street, MiMedx Group also received a Buy from Northland Securities’s Carl Byrnes in a report issued today. However, on January 14, TipRanks – xAI downgraded MiMedx Group (NASDAQ: MDXG) to a Hold.

Based on MiMedx Group’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $113.73 million and a net profit of $16.75 million. In comparison, last year the company earned a revenue of $84.06 million and had a net profit of $8.1 million

Based on the recent corporate insider activity of 26 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of MDXG in relation to earlier this year. Most recently, in November 2025, Kimberly Maersk-Moller, the CCO of MDXG sold 58,300.00 shares for a total of $432,003.00.